Geron (GERN)

• Market cap: $828M
• 1 day: -7.86%
• 5 days: -7.19%
• 1 month: -23.67%
• 3 months: -28.33%
• 6 months: 14.16%
• Year to date: -2.27%
• 1 year: 6.61%
• 5 years: -9.79%
• 10 years: -53.26%
• Sector: Healthcare
• Industry: Biotechnology

About: Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Employees: 258